在状细胞疾病中增强的血管收缩取决于ETA受体激活
John Miller Allan1, Brandon M Fox1, Malgorzata Kasztan1,2
1Section of Cardiorenal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, U.S.A.
Clinical science (London, England : 1979)
|November 11, 2024
概括
状细胞疾病 (SCD) 通过内甲素-1 (ET-1) 途径导致血管收缩增加. 用ambrisentan阻断ETA受体改善了小鼠模型和人类患者的血管功能.
科学领域:
- 血管生物学 血管生物学
- 心血管研究的心血管研究.
- 血液学 血液学 血液学
背景情况:
- 状细胞疾病 (SCD) 与血管功能障碍和活性氧物种 (ROS) 的增加有关.
- 通过ETA受体起作用的血管收缩剂内甲素-1 (ET-1) 的升高在SCD中很常见.
- 阿尔法-1上腺素受体激活会调解压力诱导的血管收缩,但其在SCD中的作用尚不清楚.
研究的目的:
- 调查SCD是否通过ET-1/ETA受体通路增强α-1上腺激素介导的血管收缩.
- 探索ETA受体对抗在SCD血管功能障碍中的治疗潜力.
主要方法:
- 使用人性化状细胞病 (HbSS) 和对照 (HbAA) 鼠标模型.
- 在大动脉组织中评估α-1上腺体受体表达.
- 测量了大动脉和动脉动脉段的血管收缩.
- 在小鼠中服用阿姆布里森坦 (ETA受体对抗剂) 和ROS食尸剂.
- 在SCD患者接受Ambrisentan或安慰剂治疗中进行了一项随机翻译研究.
主要成果:
- 与HbAA小鼠相比,HbSS小鼠在大动脉组织中显示出明显更大的α-1a上腺素受体表达.
- 来自HbSS小鼠的大动脉和动脉细分显示出增强的血管收缩.
- 在HbSS小鼠中,安布里森坦治疗和ROS清理使大动脉血管收缩正常化.
- 与安慰剂相比,接受安布里森坦治疗的SCD患者表现出腕动脉直径增加.
结论:
- ET-1/ETA受体通路与上腺体受体通路相互作用,以增强SCD中的大动脉血管收缩.
- ETA受体对抗是一种潜在的治疗策略,用于改善状细胞疾病中的血管健康.
相关概念视频
01:26Adrenergic Receptors: β Subtype
1.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.5K
01:31Adrenergic Receptors: ɑ Subtype
1.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.4K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
590
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
590
01:30Spare Receptors
3.5K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
3.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:27Adrenergic Receptors (Adrenoceptors): Classification
2.3K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.3K